Merck (MRK) Reports In-Line Q4 EPS; offers guidance

Merck (NYSE: MRK) reported Q4 EPS of $2.04, in-line with the analyst estimate of $2.04. Revenue for the quarter came in at $16.4 billion versus the consensus estimate of $16.18 billion.

GUIDANCE:

Merck sees FY2026 EPS of $5.00-$5.15, versus the consensus of $5.63. Merck sees FY2026 revenue of $65.5-67 billion, versus the consensus of $67.576 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• UBS Downgrades Merck (MRK) to Neutral
• UBS Upgrades Stockland (SGP:AU) (STKAF) to Buy
• Jaguar Health (JAGX) Tops Q2 EPS by 3647c